Etelcalcetid

What is Etelcalcetid?

Etelcalcetid is a modern medication primarily used to treat secondary hyperparathyroidism. As a calcimimetic, it mimics calcium's action on the parathyroid glands. Marketed as Parsabiv, Etelcalcetid is administered intravenously, offering a convenient option for patients undergoing hemodialysis. It represents a significant advance in managing metabolic disorders linked to chronic kidney disease (CKD), particularly those affecting calcium and phosphate balance, helping to reduce the overproduction of parathyroid hormone (PTH).

How Does Etelcalcetid Work?

Etelcalcetid's mechanism is highly targeted. It acts as an allosteric activator of the calcium-sensing receptor (CaSR), found on parathyroid glands. In CKD patients, these glands often become overactive, secreting excess PTH. Etelcalcetid binds to the CaSR, increasing its sensitivity to extracellular calcium. This enhanced sensitivity makes the parathyroid glands perceive higher calcium levels, thus reducing PTH synthesis and secretion. By lowering PTH, Etelcalcetid helps normalize calcium and phosphate metabolism, mitigating bone disease and other complications of elevated PTH.

Medical Uses

The primary indication for Etelcalcetid is the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease (CKD) who are on hemodialysis. This condition, common in CKD, results from impaired kidney function leading to phosphate retention, reduced vitamin D activation, and low calcium, all stimulating excess PTH. Uncontrolled PTH can cause renal osteodystrophy, vascular calcification, and increased cardiovascular risk. Etelcalcetid effectively lowers PTH levels into the target range, and its intravenous administration, typically post-dialysis, simplifies the treatment regimen.

Dosage

Etelcalcetid dosage is individualized based on PTH and corrected calcium levels. It's typically given as an intravenous bolus injection three times weekly, post-hemodialysis. The usual starting dose is 5 mg. Doses are adjusted (titrated) in 2.5 mg or 5 mg increments, guided by serum PTH and corrected calcium levels, aiming for therapeutic effect while minimizing hypocalcemia risk. The maximum recommended dose is 15 mg thrice weekly. Regular monitoring of serum calcium and PTH is essential for efficacy and safety. A missed dose should be given at the next hemodialysis session, resuming the regular schedule thereafter.

Side Effects

Like all medications, Etelcalcetid can cause side effects. The most common is hypocalcemia (low blood calcium), a direct result of its action. Symptoms can include muscle spasms, numbness or tingling (paresthesia), and rarely, seizures or cardiac arrhythmias. Other common effects include nausea, vomiting, diarrhea, and headache. Serious, less common side effects involve severe hypocalcemia, potentially leading to QT interval prolongation and ventricular arrhythmias. Close monitoring for hypocalcemia symptoms and regular calcium level checks are crucial. Patients with a history of seizures or cardiac issues should inform their healthcare provider.

Drug Interactions

Awareness of potential drug interactions is important with Etelcalcetid. Co-administration with other calcium-lowering agents, such as other calcimimetics (e.g., cinacalcet) or certain bisphosphonates, is generally not advised due to increased severe hypocalcemia risk. Caution is also needed with medications known to prolong the QT interval, as severe hypocalcemia can independently prolong the QT interval, raising the risk of serious cardiac arrhythmias. Patients must inform their healthcare provider about all current medications, including OTC drugs, supplements, and herbal remedies, to ensure safe treatment.

FAQ

Is Etelcalcetid the same as Parsabiv?

Yes, Parsabiv is the brand name under which Etelcalcetid is marketed.

How is Etelcalcetid administered?

It's given intravenously as a bolus injection three times weekly, typically after a hemodialysis session.

What is secondary hyperparathyroidism?

It's a condition where parathyroid glands produce excess PTH due to persistently low calcium, common in chronic kidney disease.

Can Etelcalcetid be used in patients not on dialysis?

Currently, it's indicated for secondary hyperparathyroidism in adult CKD patients on hemodialysis. Its use in non-dialysis patients for this indication is not established.

Products containing Etelcalcetid are available through trusted online pharmacies. You can browse Etelcalcetid-based medications at ShipperVIP or Medicenter.

Summary

Etelcalcetid (Parsabiv) is a vital intravenous calcimimetic agent for managing secondary hyperparathyroidism in adult patients with chronic kidney disease undergoing hemodialysis. By activating the calcium-sensing receptor on parathyroid glands, it effectively reduces parathyroid hormone secretion, normalizing calcium and phosphate levels. While generally well-tolerated, close monitoring for hypocalcemia and potential drug interactions is crucial. Its targeted action and convenient administration during dialysis make it a valuable therapeutic option for improving outcomes and preventing complications associated with uncontrolled PTH levels.